In addition, novel interventions beyond IWMPs and GLP-1 RAs should be explored, including alternative pharmacological agents and lifestyle-based therapies tailored to PCOS-specific metabolic challenges. The gene discussed is GLP1R; the disease is polycystic ovary syndrome.